Title : CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.

Pub. Date : 2020 Oct

PMID : 32945940






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. abiraterone cytochrome P450 family 17 subfamily A member 1 Homo sapiens
2 Our aim was to investigate the association between the single nucleotide polymorphism (SNP) c.-362T>C in the CYP17A1 gene, and clinical outcome in mCRPC patients treated with abiraterone. abiraterone cytochrome P450 family 17 subfamily A member 1 Homo sapiens
3 CONCLUSIONS: These findings suggest an association between CYP17A1 c.-362T>C polymorphism and poorer clinical outcome with abiraterone for mCRPC patients. abiraterone cytochrome P450 family 17 subfamily A member 1 Homo sapiens